Market Expansion Knight Therapeutics is actively expanding beyond the US into Canada and 10 Latin American countries, presenting cross-border sales opportunities for specialty pharmaceuticals in emerging markets with growing access to innovative therapies.

Recent Launches New product introductions such as TAVALISSE in Mexico and Minjuvi in Mexico indicate ongoing portfolio growth and regional commercialization activity, signaling opportunities to partner on launches, co-promotion, or in-license deals.

Financial Momentum Strong year-over-year revenue growth reflected in Q1 results and credible topline trajectory suggest expanding sales capacity and potential for additional deal structuring, marketing investments, and credit facilities to support growth.

Strategic Partnerships Existing collaborations with financial institutions (National Bank of Canada revolving facility) and past asset dispositions demonstrate a openness to strategic financing and asset-divestment/partnering models that can be leveraged for new in-licensing or distribution agreements.

Market Focus A specialized pharma approach targeting chronic immune and oncology indications in Latin America positions Knight as a partner of choice for regional access, payer negotiations, and patients seeking advanced therapies outside the US.